Clinical Trial: OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Triple Negative Breast Cancer (TNBC)
Study Type: INTERVENTIONAL
Official Title: OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer
Brief Summary:
This clinical trial aims to evaluate the efficacy, safety, and exploratory measures of liposomal doxorubicin and carboplatin combination therapy in the adjuvant setting for early stage triple negative breast cancer (TNBC) patients.The primary objective is to determine the effectiveness of liposomal doxorubicin and carboplatin in reducing the risk of recurrence for early stage TNBC patients.The secondary objectives involve characterizing the safety and toxicity profile of the combination therapy.Adverse events…
Read more